银杏叶提取物注射液+阿加曲班治疗急性脑梗死的临床价值研讨  

Study on the clinical value of Ginkgo biloba extract injection combined with argatroban in the treatment of acute cerebral infarction

作　　者：许宗英 XU Zong-ying(Department of Internal Medicine-Neurology,Yishui County People's Hospital,Linyi 276400,China)

机构地区：[1]沂水县人民医院神经内科,276400

出　　处：《中国现代药物应用》2025年第7期1-5,共5页Chinese Journal of Modern Drug Application

摘　　要：目的探究急性脑梗死以银杏叶提取物注射液联合阿加曲班治疗的临床价值。方法90例急性脑梗死患者,以随机数字表分组法分成常规组(45例)、实验组(45例)。所有患者均予以基础治疗,在此基础上,常规组提供阿加曲班单一用药方案,实验组提供银杏叶提取物注射液+阿加曲班联合用药方案。比较两组治疗效果及治疗前后疾病相关量表[简化FuglMeyer运动功能评分量表(FMA)、脑卒中患者自我效能问卷量表(SSEQ)、美国国立卫生研究院卒中量表(NIHSS)]评分、神经功能因子[神经元特异性烯醇化酶(NSE)、胶质纤维酸性蛋白(GFAP)、S100β蛋白(S-100β)]水平、炎性因子[肿瘤坏死因子-α(TNF-α)、基质金属蛋白酶-9(MMP-9)、白细胞介素-6(IL-6)]水平、凝血功能指标[纤维蛋白原(FIB)、活化部分凝血活酶时间(APTT)、凝血酶时间(TT)]。结果实验组患者的临床治疗总有效率97.78%明显高于常规组的82.22%,数据差异显著(P<0.05)。治疗后,实验组的FMA评分(73.06±6.31)分、SSEQ评分(104.05±7.77)分高于常规组的(61.24±7.28)、(91.50±5.26)分,NIHSS评分(7.00±1.44)分低于常规组的(11.15±2.20)分,数据差异显著(P<0.05)。治疗后,实验组的NSE、GFAP、S-100β水平分别为(11.05±1.98)ng/ml、(0.80±0.22)ng/ml、(0.31±0.06)μg/L,低于常规组的(13.40±2.22)ng/ml、(1.24±0.15)ng/ml、(0.50±0.10)μg/L,数据差异显著(P<0.05)。治疗后,实验组的TNF-α、MMP-9、IL-6水平分别为(15.12±6.40)ng/ml、(152.72±30.38)μg/L、(25.05±10.92)ng/L,低于常规组的(30.99±10.15)ng/ml、(220.95±35.42)μg/L、(39.22±18.75)ng/L,数据差异显著(P<0.05)。治疗后,实验组的APTT(31.60±2.18)s、TT(18.30±1.00)s长于常规组的(28.37±3.35)、(17.64±1.51)s,FIB(3.88±0.40)g/L低于常规组的(5.75±0.62)g/L,数据差异显著(P<0.05)。结论对急性脑梗死患者使用阿加曲班、银杏叶提取物注射液治疗能明显减轻炎症和神经损伤,改善病情及凝血功能,建�Objective To explore the clinical value of Ginkgo biloba extract injection combined with argatroban in the treatment of acute cerebral infarction.Methods 90 patients with acute cerebral infarction were divided into a conventional group(45 cases)and an experimental group(45 cases)using the random number table grouping method.All patients received basic treatment.On this basis,the conventional group was provided with a single medication regimen of argatroban,the experimental group was provided with combination medication regimen of Ginkgo biloba extract injection and argatroban.Comparison of therapeutic effect,disease-related scale[Fugl-Meyer Assessment(FMA),Stroke Self-efficacy Questionnaire(SSEQ),National Institutes of Health Stroke Scale(NIHSS)]scores,levels of neurological functional factors[neuron-specifice nolase(NSE),glial fibrillary acidic protein(GFAP),S-100β],levels of inflammatory factors[tumor necrosis factor-α(TNF-α),matrix metalloproteinase-9(MMP-9),interleukin-6(IL-6)],and coagulation function indicators[fibrinogen(FIB),activated partial thromboplastin time(APTT),thrombin time(TT)]before and after treatment between the two groups.Results The total effective rate of the experimental group was 97.78%,which was significantly higher than 82.22%of the conventional group,and the data difference was significant(P<0.05).After treatment,the experimental group had FMA score of(73.06±6.31)points and SSEQ score of(104.05±7.77)points,which were higher than(61.24±7.28)and(91.50±5.26)points in the conventional group;the experimental group had a lower NIHSS score of(7.00±1.44)points than(11.15±2.20)points in the conventional group;the data difference was significant(P<0.05).After treatment,the levels of NSE,GFAP and S-100βin the experimental group were(11.05±1.98)ng/ml,(0.80±0.22)ng/ml and(0.31±0.06)μg/L,which were lower than(13.40±2.22)ng/ml,(1.24±0.15)ng/ml and(0.50±0.10)μg/L in the conventional group,and the data difference was significant(P<0.05).After treatment,the levels of TNF-α,MMP-9 and I

关 键 词：急性脑梗死 阿加曲班 银杏叶提取物注射液 治疗效果 

分 类 号：R743.33[医药卫生—神经病学与精神病学]